Hong et al developed the Tumor Recurrent Prognostic Index (TRPI) for use in patients who have had a liver transplant for a locally advanced intrahepatic or hilar cholantiocarcinoma. This can help to identify a patient who may benefit from more aggressive management. The authors are from the University of California at Los Angeles.
Parameters:
(1) focality of the tumor
(2) perineural invasion
(3) lymphovascular invasion
(4) infiltrative growth pattern
(5) neoadjuvant therapy
(6) history of primary sclerosing cholangitis (PSC)
(7) location of the tumor
|
Parameter |
Finding |
Points |
|
focality |
unifocal |
0 |
|
|
multifocal |
4 |
|
perineural invasion |
absent |
0 |
|
|
present |
4 |
|
lymphovascular invasion |
absent |
0 |
|
|
present |
1 |
|
infiltrative growth pattern |
absent |
0 |
|
|
present |
3 |
|
neoadjuvant therapy |
administered |
0 |
|
|
not administered |
3 |
|
history of PSC |
absent |
0 |
|
|
present |
2 |
|
location of the tumor |
intrahepatic |
0 |
|
|
hilar |
1 |
total score =
= SUM(points for all 7 parameters)
Interpretation:
• minimum TRPI: 0
• maximum TRPI 18
• The higher the TRPI the greater the likelihood of recurrence.
|
Total TRPI |
Risk Group |
Recurrence |
|
0 to 3 |
low |
22% at 5 years |
|
4 to 7 |
intermediate |
80% at 5 years |
|
8 or more |
high |
100% at 2 years |
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
ICD-10: ,
